MAPK11 and amyotrophic lateral sclerosis: The inhibition of MAPK11-involved astrocyte inflammation and the enhancement of antioxidant capacity are essential mechanisms by which MSC-Exos improve the prognosis of amyotrophic lateral sclerosis (ALS) (Provenzano et al. 2022).